|
J Biol Chem, Vol. 273, Issue 23, 14545-14549, June 5, 1998
Cholecystokinin Decreases Intestinal Hexose Absorption by a
Parallel Reduction in SGLT1 Abundance in the Brush-Border
Membrane*
Andrew J.
Hirsh and
Christopher I.
Cheeseman§
From the Membrane Transport Group, Department of Physiology,
University of Alberta, Edmonton, Alberta T6G 2H7, Canada
 |
ABSTRACT |
The dual lumenaly and vascularly perfused small
intestine was used to determine the mechanism by which cholecystokinin
octapeptide (CCK-8) decreases the rate of glucose absorption. With
CCK-8 in the vascular perfusate the rate of
3-O-methyl-D-glucose absorption decreased,
whereas the rate of D-fructose absorption was unaffected. The substrate pool size within the tissue during steady-state transport, in the presence and absence of CCK-8, was estimated by
compartmental analysis of the
3-O-methyl-D-glucose washout into the vascular
bed. When CCK-8 was included in the vascular perfusate, the absorptive
cell pool size decreased when compared with untreated tissue. Both the
steady-state hexose absorption data and the washout studies indicated
that the locus of action of CCK-8 was the SGLT1 transporter located in
the brush-border membrane. The SGLT1 protein abundance in isolated
brush-border membranes, as quantified by Western blotting, showed a
decrease that paralleled the decrease in the steady-state transport
rate induced by CCK-8. These results indicate that CCK-8 diminishes the
rate of intestinal hexose absorption by decreasing SGLT1 protein abundance in the brush-border membrane of the rat jejunum and therefore
provides evidence for acute enteric hormonal regulation of the rate of
glucose absorption across the small intestine.
 |
INTRODUCTION |
The systemic plasma glucose concentration is normally maintained
within a fairly narrow range (4.5-6.5 mM) even during
episodic eating. The regulation of this homeostatic process is provided by multiple systems in the body. One of the systems involved in delivering glucose to the systemic circulation through the absorption of carbohydrate-digested products is the small intestine. To this end,
the rate at which hexoses are absorbed across the small intestine could
be an important factor in influencing the plasma hexose concentration.
The gastrointestinal peptide,
CCK,1 is known to modulate
intestinal glucose absorption indirectly by delaying gastric emptying (1-3) and recently has been shown to also directly regulate the rate
of glucose absorption across the small intestine (4). Hormones known to
increase intestinal hexose absorption are insulin, gastric inhibitory
polypeptide, and glucagon-like peptide-2 (5-7). However, mechanism(s)
involved in the CCK-induced decrease of hexose absorption have not been
identified (4). Possible mechanisms involved in altering hexose
transport rates include changes in the electrochemical gradient for
sodium (8), the affinity of the transporter for glucose (9), and the
amount of functional transporter present in the membrane (10). Recent
evidence indicates that rapid up-regulation of glucose transport in
jejunal enterocytes occurs by a change in the abundance of SGLT1 in the
apical membrane (6, 11).
The transcellular transport of aldoses (D-glucose,
3-O-MG, and D-galactose) across the absorptive
epithelium (enterocytes) involves entry across the BBM using the
Na+-dependent transporter (SGLT1) (12, 13)
followed by exit across the BLM via a Na+-independent
transporter (GLUT2) (14). D-Fructose, a ketose, enters the
enterocyte using a different carrier, a Na+-independent
transporter (GLUT5) (14), but exits using the same transporter (GLUT2)
as the aldoses in the BLM (15) (Fig. 1). Thus, by applying this model and monitoring both aldose and ketose absorption the results would allow for a better understanding of the
specificity and locus of action of CCK-8 on hexose absorption. The
dually perfused jejunal preparation has been useful in determining the
effects of hormones responsible for regulating carbohydrate absorption
(4, 7), the locus of action of inhibitors of specific hexose
transporters by compartmental analysis (16), and the simultaneous
measurement of aldose and ketose absorption (17). To establish if the
CCK-8-induced decrease in hexose absorption involves changing the
number of transporters in the BBM we measured in each tissue the rate
of hexose absorbed over time, using the dually perfused jejunum and
then determined the abundance of SGLT1 in the BBM at the specific
transport rates at the same perfusion times.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 1.
A schematic representing an enterocyte in the
rat small intestine showing hexose transporter locations. The
brush-border membrane is the area of membrane exposed to the lumenal
contents. The basolateral membrane is the remaining plasma membrane.
Arrows indicate the prevalent direction of movement of the
substrate. It should be noted that galactose (which was not used in
this study) uses the same transporters as glucose and
3-O-MG.
|
|
In this report we demonstrate that CCK-8 specifically inhibits aldose
absorption by decreasing the abundance of the SGLT1 protein located in
the BBM of the rat small intestine. Our results establish that the rate
at which the jejunum absorbs aldoses is subjected to rapid and specific
enteric peptide control of the rate of entry across the BBM.
 |
EXPERIMENTAL PROCEDURES |
Dually Perfused in Situ Jejunum--
Male Sprague-Dawley rats
(200-350 g) were supplied by Taconic Farms, Germantown, NY. The rats
were fed a standard chow diet (Purina PMI Rodent Food) and water
ad libitum. Before the start of the experiment, food was
withdrawn for approximately 24 h to minimize intestinal lumenal
contents during surgery. The study was approved by the Health Sciences
Animal Welfare Committee from the Faculty of Medicine. All rats were
anesthetized prior to surgery using sodium pentobarbital given by
intraperitoneal injection (60 mg/kg body weight) and placed on a heated
(37 °C) surgical table. The techniques and apparatus used in these
experiments were similar to those described previously (4, 17). After performing a laparotomy, the blood supply to the spleen, rectum, colon,
cecum, stomach, and ileum were tied off and the tissues removed; the
vasculature to the pancreas and duodenum were also ligated. A 35-cm
segment of jejunum, starting 5 cm distal from the ligament of Trietz,
was isolated and the lumenal contents removed by gently flushing with
20 ml of warm saline (0.9%), and the jejunum was cannulated at both
ends. The lumen was perfused with a Krebs-bicarbonate saline solution
(120 mM NaCl, 4 mM KCl, 2.5 mM
MgSO4, 1.2 mM KH2PO4,
25 mM NaHCO3, 1 mM
CaCl2) using a GILSON Minipuls 2 pump (Mandel Scientific
Ltd). The solution, containing 5 mM 3-O-MG or 5 mM 3-O-MG and 5 mM
D-fructose, was maintained at 37 °C and gassed with 95%
O2, 5% CO2. Isotopically labeled hexoses, 10 µCi of either
3-O-methyl-D-[1-3H]glucose, or
both 3-O-methyl-D-[1-3H]glucose
and D-[U-14C]fructose (Amersham Canada Ltd.),
were added to the lumenal circuit immediately after portal vein
cannulation. The single-pass lumenal circuit was perfused at a flow
rate of 1.6 ml/min, and the solution was segmented by 95%
O2, 5% CO2 gas bubbles. The gas bubbles were introduced into the lumenal perfusate through a Y piece at a flow rate
which ensured that bubbles occupied the diameter of the perfusion tube.
This not only exposed the tissue to a saturating gas partial pressure,
but also helped to mix the solution in the tissue lumen. After a
single-pass through the segment of jejunum the lumenal perfusate was
discarded. The aorta, proximal to the superior mesenteric artery, was
ligated just prior to insertion of a cannula into the superior
mesenteric artery. The single-pass vascular circuit was perfused at a
rate of 1.6 ml/min with fresh Krebs-bicarbonate saline solution,
containing 5 mM D-glucose, 0.034 mM
streptomycin sulfate, 5 mM L-glutamine, 1120 USP units heparin, and 10% w/v Ficoll 70 (Sigma-Aldrich Canada Ltd.)
as a plasma expander, which was maintained at 37 °C and gassed with
95% O2, 5% CO2 maintaining the pH at 7.4. Once the vascular circuit was established, the rat was euthanized and
the vascular perfusate was collected via a cannula placed in the
hepatic portal vein. CCK-8 was added to the vascular perfusate at final
concentrations described in the appropriate figure legend. The effluent
was collected continuously for up to 80 min using a GILSON (Mandel
Scientific Ltd) fraction collector. Statistical analysis was performed
using analysis of variance (repeated measure).
Washout Studies in the Dually Perfused Jejunum--
This
procedure is similar to the one used by Boyd and Parsons (16). This
washout model is useful for indirectly indicating the locus of CCK
action. When the labeled 3-O-MG is washed out in the
presence of an equimolar concentration of unlabeled mannitol in the
lumen, the rate of washout into the vascular bed can be described by
the sum of two exponential terms (assuming a two-compartmental model
applies). The contributing compartments are a fast releasing (vascular
flow rate dependent) and a slow releasing one (vascular flow rate
independent), which represent: 1) Q01 mucosal
epithelium layer and 2) Q02 deeper submucosal
(muscle) layer. Assuming that each pool unloads independently, then
each pool will have its own rate constant: the fast,
K1 and the slow, K2.
Statistical analysis was performed using unpaired Student's
t test.
Preparation of Brush-border Membrane Vesicles--
The frozen
mucosal scrapings, taken from tissue used to measure hexose absorption
after 25 min of perfusion with or without CCK-8 present in the vascular
infusate, were thawed at room temperature and then placed in 40 ml of
ice-cold mannitol/Tris buffer (300 mM mannitol, 5 mM EGTA, 12 mM Tris-HCl, pH 7.4, 0.1 mM phenylmethylsulfonyl fluoride). The tissue was
homogenized with a Polytron homogenizer (setting 5) for 2 min before
addition of magnesium chloride to a final concentration of 12 mM. After stirring the solution on ice for 15 min the
solution was centrifuged at 3,000 × g (Sorval RC5C)
for 15 min to remove debris. The supernatant was further centrifuged at
37,000 × g for 30 min and the pellet homogenized in a
mannitol/Tris buffer (150 mM mannitol, 2.5 mM
EGTA, 6 mM Tris-HCl, pH 7.4, 0.05 mM
phenylmethylsulfonyl fluoride) with a glass homogenizer before further
addition of magnesium chloride (12 mM). After stirring on
ice the centrifugation was repeated as before and the pellet was then
washed with 300 mM mannitol, 5 mM Tris-HCl, pH
7.4, before repelleting. This vesicle preparation was diluted in 300 mM mannitol, 5 mM Tris-HCl, pH 7.4, to an
appropriate protein concentration, usually 8 mg/ml.
Western Blotting--
Brush-border membrane vesicles (see above)
(40 µg) from control and CCK-8 treated tissue were solubilized in
Laemmli sample buffer and run on a 10% sodium dodecyl
sulfate-polyacrylamide gel using a Mini-PROTEAN II cell (Bio-Rad,
Canada). The proteins were transferred onto nitrocellulose membrane
(Millipore) by electrotransfer for 90 min, at 4 °C, using the Mini
Trans-Blot Cell (Bio-Rad, Canada). Blocking of the membrane was carried
out in 3% nonfat milk in PBST (0.05% Tween 20, phosphate-buffered
saline (137 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 4.3 mM
Na2HPO4), pH 7.4, for 1 h. The blots were
incubated in 3% nonfat dry milk in PBST with 1:1,000 rabbit polyclonal
antibody to rat SGLT1 (Chemicon International Inc., Temecula, CA)
overnight at 4 °C. The membrane was washed three times in 3% nonfat
dry milk, PBST for 15 min. The nitrocellulose membrane was then
incubated with a secondary antibody, anti-rabbit IgG coupled to
horseradish peroxidase diluted 1:2,000 in 3% nonfat dry milk, PBST for
1 h. Three subsequent washes followed as described above. Finally,
the membrane was treated with the ECL detection solution (Amersham
Canada Ltd.) before exposing the Kodak XAR-5 film with an intensifying
screen from 1 to 4 min. One distinct band was detected by this method
with an apparent molecular mass of 71 kDa.
Immunoblot Quantitative Analysis--
Immunoblots were scanned
with a Scanjet 4C flatbed scanner (Hewlett Packard, Palo Alto, CA),
calibrated with a Kodak gray scale. Scanned images were quantified
using NIH Image 1.60 software. Results are reported as percentage from
protein abundance at steady state rate after 25 min of perfusion with 5 mM 3-O-MG. Statistical analysis was performed
using Student's t test.
 |
RESULTS |
To determine the specificity of CCK-8's actions and to identify
which of the transporter proteins are involved in the CCK-induced inhibition of intestinal hexose absorption, both the rates of D-fructose and 3-O-MG absorption were measured
simultaneously in dually perfused jejuna (Fig.
2). After the steady-state rate of
3-O-MG transport was achieved (12 min), the rate
significantly diminished after CCK-8, 8 pM (the maximum
inhibitory concentration) (4) was added to the vascular infusate. The
steady-state rate of 3-O-MG in this preparation is normally
maintained for a minimum of 90 min. in the absence of vascular CCK-8
(4). The steady-state rate of fructose absorption was slower than that
of 3-O-MG, and was achieved more slowly (23 min). Also, when
CCK-8 was added to the vascular perfusate fructose transport was
unaffected (Fig. 2).

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 2.
CCK-8 decreases the rate of
3-O-MG absorption but not that of
D-fructose. The jejunal lumen was perfused with Krebs
bicarbonate saline, segmented with carbogen gas bubbles, at a flow rate
of 1.6 ml/min. 3H-labeled 3-O-MG and
14C-labeled D-fructose were added to the
lumenal circuit (containing 5 mM 3-O-MG and 5 mM D-fructose) within 3 min after cannulation
of the portal vein. The vascular bed was perfused with a Ficoll based
Krebs solution as described under "Experimental Procedures," at the
same flow rate as in the lumen and the vascular effluent was collected
over a 70-min period via a cannula in the portal vein. The solid
line ( ) represents the rate of appearance of labeled
3-O-MG in the vascular effluent. The dashed line
( ) represents the appearance of labeled D-fructose in
the vascular effluent. The solid horizontal black bar
represents 8 pM CCK-8 in the vascular infusate. Data points
represent the mean rate of appearance of 3-O-MG and
D-fructose, expressed as absorption in µmol/g dry
weight/h ± S.E., n = 3 (**p < 0.001, any point following from the same series is significant).
|
|
The fructose data indicates that the locus of CCK-8 action is specific
for SGLT1 in the BBM (refer to Fig. 1) so we used compartmental analysis of six separate washout studies of 3-O-MG from the
small intestine to confirm this observation. Addition of CCK-8 (8 pM) to the vascular perfusate caused a significant decline
in the steady-state transport rate (Fig.
3), and analysis of the washout using
double exponential decay (Enzfitter software, Elseivier) showed CCK-8
significantly decreased the pool size, Q01
within the epithelium. In contrast the second pool,
Q02, and the rate constants
K1 and K2 were not
significantly reduced by CCK-8 compared with control conditions
(steady-state rate) (Fig. 4, A
and B, and Table I).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 3.
CCK-8 decreases the amount of
3-O-MG entering the enterocytes. The jejunal lumen was
perfused with Krebs bicarbonate saline, segmented with carbogen gas
bubbles, at a flow rate of 1.6 ml/min. 3H-labeled
3-O-MG was added to the lumenal circuit (containing 5 mM 3-O-MG) within 3 min after cannulation of the
portal vein. The vascular bed was perfused with a Ficoll-based Krebs
solution as described under "Experimental Procedures," at the same
flow rate as in the lumen. The vascular effluent was collected over a
38-min period via a cannula in the portal vein. The solid
line ( ) represents the rate of appearance of labeled
3-O-MG in the vascular effluent. The dashed line
( ) represents appearance of labeled 3-O-MG in the
vascular effluent with 8 pM CCK-8 in the vascular infusate.
The horizontal solid black bar represents the lumenal
washout (0 mM 3-O-MG) in the presence of 5 mM mannitol. Data points represent the mean rate of
appearance of 3-O-MG expressed as absorption in micromoles/g
dry weight/h ± S.E., n = 3 (*p < 0.05).
|
|

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 4.
CCK-8 decreases the pool of
3-O-MG in the enterocytes. Panel A is a
representative plot of 3H-labeled 3-O-MG, using
double exponential decay with proportional weighting and plotted as the
natural log (insets), in the vascular effluent expressed as
micromoles/g dry weight/h during washout with mannitol, and before
treatment with vascular CCK-8. The lumenal perfusate contained 5 mM 3-O-MG, the horizontal solid line
represents the lumenal washout (0 mM 3-O-MG) in
the presence of 5 mM mannitol. Panel B is a
representative plot of the washout rate when CCK-8 (8 pM)
was included in the vascular infusate.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Effect of CCK-8 on pool sizes and rates of washout of 3-O-MG in the
dually perfused jejunum
Control values were obtained from animals when CCK-8 was not added to
the vascular infusate, whereas CCK-8 values were from animals when 8 pM CCK-8 was included in the vasculature over 35 min.
Values are recorded as mean ± S.E. from three animals (arbitrary
values) and were calculated using double exponential decay (Enzfitter)
where the initial values were the pool sizes Q01,
Q02, and K1 was the first rate
constant and K2 was the second rate constant
(min 1).
|
|
To determine the mechanism involved in the CCK-8-induced decrease in
SGLT1-mediated transport, we monitored 3-O-MG absorption and
then measured the abundance of SGLT1 protein in tissue after a 25-min
perfusion either with or without CCK-8 (8 pM) present in
the vascular infusate. A significant decrease in SGLT1 abundance (Fig.
5B) caused by the addition of
CCK-8 (8 pM) to the vascular infusate was shown to parallel
a decrease in the 3-O-MG absorption (Fig. 5A),
which occurred within 25 min of CCK-8 addition to the vascular circuit.
To help make the comparison and determine statistical significance the
data were converted to a percent of control values, the change in
transport rate and SGLT1 abundance induced by the presence of CCK-8 (8 pM) was 25.2 ± 4 and 36 ± 6.7, respectively, and the changes induced by CCK-8 were not significantly different from
each other (Fig. 5C).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 5.
CCK-8 decreases 3-O-MG absorption
in parallel to a reduction in SGLT1 abundance in the brush-border
membrane. Absorption of labeled 3-O-MG was measured for
25 min using the dually perfused preparation (panel A) as
described under "Experimental Procedures." After collecting the
vascular effluent the jejunal segment was excised from the animal,
rinsed with ice-cold Krebs solution, opened longitudinally, and the
mucosa scraped off using a glass slide and immediately snap-frozen in
liquid nitrogen. The mucosal scrapings were used to make BBM and
Western blotted, the SGLT1 protein was immunodetected using an SGLT1
antibody (panel B, a, protein density after 25 min of lumenal perfusion with 5 mM 3-O-MG
(steady-state rate); b, c, d, and
e (each a separate experiment, n = 4)) after
25 min with 8 pM CCK-8 in the vascular circuit and 5 mM 3-O-MG in the lumenal perfusate. In
panel C the black columns represent protein
abundance (arbitrary units) and the white columns represent
the absorption (% of control). Values represent mean ± S.E.
where 100% represents the protein abundance and the absorption rate at
steady-state without CCK-8 present, n = 4 (*p < 0.05).
|
|
 |
DISCUSSION |
Slowing the rate at which D-glucose enters the
systemic circulation would improve the ability of the other glucose
homeostatic systems to handle the substrate load and therefore
contribute to the normalization of the plasma glucose concentration.
The results from the simultaneous fructose and 3-O-MG
absorption study suggests that GLUT5 in the BBM and GLUT2 in the BLM of
the enterocyte, both of which transport fructose, are not affected by
CCK-8 and supports the view that CCK acts specifically on SGLT1 (refer
to Fig. 1). The only alternative explanation for this data could be
that CCK selectively changes the affinity of GLUT2 in the BLM for
aldoses and not fructose. What is also noteworthy from the hexose
absorption measurements is the lower rate of fructose absorption (2.7-fold slower) compared with that of 3-O-MG (Fig. 2).
This slower fructose absorption in rat jejunum is similar to that
reported by Holloway and Parsons (18) using a similar dual perfusion technique. The slower rate of fructose absorption we observed could be
explained by the different transporters employed in aldose and ketose
absorption. D-Fructose entry into the enterocyte is not
driven by the Na+ gradient, but is apparently concentration
driven, a consequence of the metabolism that occurs in the enterocytes.
It is likely that the metabolic fate of fructose is one of the primary
determinants in regulating absorption and therefore the rate of
D-fructose absorption depends significantly on the
animal's ability to metabolize fructose (19). In order to support our
hypothesis that CCK-8 acts specifically on the SGLT1 transporter,
indicated by the fructose absorption studies, we used compartmental
analysis of 3-O-MG washout in the dually perfused jejunum,
which showed a significant decrease in the tissue pool size. This
method was used previously to indicate the site of the rate-limiting
step for hexose and amino acid transport across the enterocyte (16, 20,
21) and our data parallel those of Boyd and Parsons (16), who showed
that phloridzin, which is known to act specifically on SGLT1,
significantly decreased the Q01 without
affecting the washout rate constant. In these experiments CCK-8 also
significantly reduced the tissue pool size of 3-O-MG which
could only occur if entry across the BBM was reduced, or exit across
the BLM was increased. If anything, CCK-8 slowed the exit as measured
by the rate constant K1, although the effect was
not statistically significant. Therefore, the reduced tissue pool size
most likely results from a decreased uptake across the BBM. Taken
together, the compartmental analysis data and the unaffected fructose
absorption indicate that CCK's action is to reduce the entry of
aldoses across the BBM, i.e. substrates specific for SGLT1.
The immunoblots showing a decrease in SGLT1 indicate that CCK is
involved in a rapid post translational event which lowers SGLT1
abundance. This could mean that CCK regulates SGLT1 transporter translocation in a manner similar to that for GLUT1 and GLUT4, which
occurs in fat and muscle tissue (22). Additional evidence which
supports this type of regulation in the intestine includes the fact
that changes occur in the surface area of enterocytes when glucose
absorption is increased with epidermal growth factor (23). Furthermore,
GLP-2 and epinephrine have also been shown to increase SGLT1 abundance
in this tissue (6, 11). There is also some evidence, using
Xenopus oocytes expressing SGLT1, that protein kinase A and
C modulate exocytosis and endocytosis, respectively, of vesicles
containing SGLT1 (24). Because the physiological effect of CCK occurs
at the BBM, when the peptide is added to the vascular circuit, it is
likely that this action is mediated by a cytosolic second messenger and
does not occur directly through a receptor mediated endo or exocytosis.
The decrease in SGLT1 abundance could result from a reduced rate of
insertion of SGLT1 into the BBM, from an increased rate of removal from the BBM, or by decreasing a recycling step. However, the decrease in
SGLT1 abundance indicates that the action is not likely to be mediated
through the proposed regulatory subunit of SGLT1 (RS1), unless RS1 acts
as a chaperone (25). Also, evidence has suggested that regulation of
SGLT1 in rat jejunum is mediated through a protein kinase A
phosphorylation (11), however there are no apparent protein kinase A
consensus phosphorylation sites on the rat SGLT1 (24). This suggests
that phosphorylation would likely involve another component involved in
insertion or removal of SGLT1 from the BBM, as mentioned above.
The establishment of a rapid negative feedback pathway involving CCK
for controlling hexose absorption in the small intestine extends the
role of the tissue in glucose homeostasis. Instead of an immediate and
rapid absorption of all SGLT1 specific substrates, there is a slowing
in the rate of transfer while the meal is passing along the small
intestine. This would allow for a more gradual introduction of glucose
into the body, and would give the other tissues more time to handle
this nutrient and serve to help maintain a steady plasma glucose
concentration.
 |
ACKNOWLEDGEMENT |
We are grateful to Dr. S. Barton for assisting
in the preparation of this manuscript.
 |
FOOTNOTES |
*
This work was supported by the Canadian Diabetes
Association.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Supported by a J. B. Collip Studentship from the Muttart
Diabetes and Research Training Center.
§
To whom correspondence should be addressed: University of Alberta,
Dept. of Physiology, 7-55 Medical Sciences Bldg., Edmonton, Alberta T6G
2H7, Canada. Tel.: 403-492-2620; Fax: 403-492-8915; E-mail:
chris.cheeseman{at}ualberta.ca.
1
The abbreviations used are: CCK,
cholecystokinin; CCK-8, cholecystokinin octapeptide; 3-O-MG,
3-O-methyl-D-glucopyranose; BBM, brush-boarder
membrane; BLM, basolateral membrane.
 |
REFERENCES |
-
Debas, H.,
Farooq, O.,
and Grossman, M.
(1975)
Gastroenterology
68,
1211-1217[Medline]
[Order article via Infotrieve]
-
Liddle, R. A.,
Morita, E. T.,
Conrad, C. K.,
and Williams, J. A.
(1986)
J. Clin. Invest.
77,
992-996
-
Liddle, R. A.,
Rushakoff, R. J.,
Morita, E. T.,
Beccaria, l.,
Carter, J. D.,
and Goldfine, I. D.
(1988)
J. Clin. Invest.
81,
1675-1681
-
Hirsh, A. J.,
Tsang, R.,
Kammila, S.,
and Cheeseman, C. I.
(1996)
Am. J. Physiol.
271,
G755-G761[Abstract/Free Full Text]
-
Cheeseman, C. I.,
and Tsang, R.
(1996)
Am. J. Physiol.
271,
G477-G482[Abstract/Free Full Text]
-
Cheeseman, C. I.
(1997)
Am. J. Physiol.
273,
R1965-R1971[Abstract/Free Full Text]
-
Pennington, A. M.,
Corpe, C. P.,
and Kellett, G. L.
(1994)
J. Physiol.
478,
187-193[Abstract/Free Full Text]
-
Hopfer, U.
(1975)
Proc. Natl. Acad. Sci. U. S. A.
72,
2027-2031[Abstract/Free Full Text]
-
Debnam, E. S.,
and Levin, R. J.
(1975)
J. Physiol.
252,
681-700[Abstract/Free Full Text]
-
Debnam, E. S.,
Smith, M. W.,
Sharp, P. A.,
Srai, S. K.,
Turvey, A.,
and Keable, S. J.
(1995)
Eur. J. Phys.
430,
151-159[CrossRef][Medline]
[Order article via Infotrieve]
-
Ishikawa, Y.,
Eguchi, T.,
and Ishida, H.
(1997)
Biochim. Biophys. Acta
1357,
306-318[Medline]
[Order article via Infotrieve]
-
Crane, R. K.
(1962)
Fed. Proc.
21,
891-895
-
Hediger, M. A.,
Coady, M. J.,
Ikeda, T. S.,
and Wright, E. M.
(1987)
Nature
330,
379-381[CrossRef][Medline]
[Order article via Infotrieve]
-
Davidson, N. O.,
Hausman, A. M.,
Ifkovits, C. A.,
Buse, J. B.,
Gould, G. W.,
Burant, C. F.,
and Bell, G. I.
(1992)
Am. J. Physiol.
262,
C795-C800[Abstract/Free Full Text]
-
Cheeseman, C. I.
(1993)
Gastroenterology
105,
1050-1056[Medline]
[Order article via Infotrieve]
-
Boyd, C. A. R.,
and Parsons, D. S.
(1978)
J. Physiol.
274,
17-36[Abstract/Free Full Text]
-
Hirsh, A. J.,
Yao, S. Y. M.,
Young, J. D.,
and Cheeseman, C. I.
(1997)
Gastroenterology
113,
205-211[CrossRef][Medline]
[Order article via Infotrieve]
-
Holloway, P. A.,
and Parsons, D. S.
(1984)
Biochem. J.
222,
57-64[Medline]
[Order article via Infotrieve]
-
Bismut, H.,
Hers, H.-G.,
and Van Schaftingen, E.
(1993)
Eur. J. Biochem.
213,
721-726[Medline]
[Order article via Infotrieve]
-
Boyd, C. A. R.,
and Parsons, D. S.
(1979)
J. Physiol.
287,
371-391[Abstract/Free Full Text]
-
Cheeseman, C. I.
(1981)
J. Physiol.
317,
91-102[Abstract/Free Full Text]
-
James, D. E.,
Brown, R.,
Navarro, J.,
and Pilch, P. F.
(1988)
Nature
333,
183-185[CrossRef][Medline]
[Order article via Infotrieve]
-
Hardin, J. A.,
Buret, A.,
Meddings, J. B.,
and Gall, D. G.
(1993)
Am. J. Physiol.
264,
G312-G318[Abstract/Free Full Text]
-
Hirsch, J. R.,
Loo, D. D. F.,
and Wright, E. M.
(1996)
J. Biol. Chem.
271,
14740-14746[Abstract/Free Full Text]
-
Veyhl, M.,
Spangenberg, J.,
Puschel, B.,
Poppe, R.,
Dekel, C.,
Fritzche, G.,
Haase, W.,
and Koepsell, H.
(1993)
J. Biol. Chem.
268,
25041-25053[Abstract/Free Full Text]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. P. Wong, E. S. Debnam, and P. S. Leung
Involvement of an enterocyte renin angiotensin system in the local control of SGLT1-dependent glucose uptake across the rat small intestinal brush border membrane
J. Physiol.,
October 15, 2007;
584(2):
613 - 623.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Ducroc, T. Voisin, A. El Firar, and M. Laburthe
Orexins Control Intestinal Glucose Transport by Distinct Neuronal, Endocrine, and Direct Epithelial Pathways
Diabetes,
October 1, 2007;
56(10):
2494 - 2500.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Vernaleken, M. Veyhl, V. Gorboulev, G. Kottra, D. Palm, B.-C. Burckhardt, G. Burckhardt, R. Pipkorn, N. Beier, C. van Amsterdam, et al.
Tripeptides of RS1 (RSC1A1) Inhibit a Monosaccharide-dependent Exocytotic Pathway of Na+-D-Glucose Cotransporter SGLT1 with High Affinity
J. Biol. Chem.,
September 28, 2007;
282(39):
28501 - 28513.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. J. Mace, J. Affleck, N. Patel, and G. L. Kellett
Sweet taste receptors in rat small intestine stimulate glucose absorption through apical GLUT2
J. Physiol.,
July 1, 2007;
582(1):
379 - 392.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Veyhl, T. Keller, V. Gorboulev, A. Vernaleken, and H. Koepsell
RS1 (RSC1A1) regulates the exocytotic pathway of Na+-D-glucose cotransporter SGLT1
Am J Physiol Renal Physiol,
December 1, 2006;
291(6):
F1213 - F1223.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Mate, A. Barfull, A. M. Hermosa, L. Gomez-Amores, C. M. Vazquez, and J. M. Planas
Regulation of sodium-glucose cotransporter SGLT1 in the intestine of hypertensive rats
Am J Physiol Regulatory Integrative Comp Physiol,
September 1, 2006;
291(3):
R760 - R767.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. L. Kellett and E. Brot-Laroche
Apical GLUT2: A Major Pathway of Intestinal Sugar Absorption
Diabetes,
October 1, 2005;
54(10):
3056 - 3062.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Ducroc, S. Guilmeau, K. Akasbi, H. Devaud, M. Buyse, and A. Bado
Luminal Leptin Induces Rapid Inhibition of Active Intestinal Absorption of Glucose Mediated by Sodium-Glucose Cotransporter 1
Diabetes,
February 1, 2005;
54(2):
348 - 354.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Osswald, K. Baumgarten, F. Stumpel, V. Gorboulev, M. Akimjanova, K.-P. Knobeloch, I. Horak, R. Kluge, H.-G. Joost, and H. Koepsell
Mice without the Regulator Gene Rsc1A1 Exhibit Increased Na+-D-Glucose Cotransport in Small Intestine and Develop Obesity
Mol. Cell. Biol.,
January 1, 2005;
25(1):
78 - 87.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Kimura, K. K. Buddington, and R. K. Buddington
The Influence of Estradiol and Diet on Small Intestinal Glucose Transport in Ovariectomized Rats
Experimental Biology and Medicine,
March 1, 2004;
229(3):
227 - 234.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. L Kellett
The facilitated component of intestinal glucose absorption
J. Physiol.,
March 15, 2001;
531(3):
585 - 595.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|